Compare Novartis with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DIVIS LABORATORIES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DIVIS LABORATORIES NOVARTIS/
DIVIS LABORATORIES
 
P/E (TTM) x 834.6 48.2 1,731.3% View Chart
P/BV x 25.1 8.8 283.9% View Chart
Dividend Yield % 1.8 0.7 254.6%  

Financials

 NOVARTIS   DIVIS LABORATORIES
EQUITY SHARE DATA
    NOVARTIS
Mar-19
DIVIS LABORATORIES
Mar-19
NOVARTIS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9801,639 59.8%   
Low Rs6001,115 53.8%   
Sales per share (Unadj.) Rs198.7186.3 106.7%  
Earnings per share (Unadj.) Rs21.051.0 41.1%  
Cash flow per share (Unadj.) Rs22.357.3 38.8%  
Dividends per share (Unadj.) Rs10.0016.00 62.5%  
Dividend yield (eoy) %1.31.2 108.9%  
Book value per share (Unadj.) Rs307.5261.8 117.5%  
Shares outstanding (eoy) m24.69265.47 9.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.07.4 53.8%   
Avg P/E ratio x37.727.0 139.4%  
P/CF ratio (eoy) x35.524.0 147.8%  
Price / Book Value ratio x2.65.3 48.8%  
Dividend payout %47.731.4 151.9%   
Avg Mkt Cap Rs m19,508365,592 5.3%   
No. of employees `0000.611.8 4.9%   
Total wages/salary Rs m1,1715,423 21.6%   
Avg. sales/employee Rs Th8,445.44,175.1 202.3%   
Avg. wages/employee Rs Th2,015.7457.7 440.4%   
Avg. net profit/employee Rs Th891.01,141.8 78.0%   
INCOME DATA
Net Sales Rs m4,90749,463 9.9%  
Other income Rs m7831,556 50.3%   
Total revenues Rs m5,68951,019 11.2%   
Gross profit Rs m12318,718 0.7%  
Depreciation Rs m321,689 1.9%   
Interest Rs m1635 45.4%   
Profit before tax Rs m85818,551 4.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3405,023 6.8%   
Profit after tax Rs m51813,527 3.8%  
Gross profit margin %2.537.8 6.6%  
Effective tax rate %39.627.1 146.4%   
Net profit margin %10.627.3 38.6%  
BALANCE SHEET DATA
Current assets Rs m8,05546,501 17.3%   
Current liabilities Rs m1,8508,468 21.8%   
Net working cap to sales %126.476.9 164.4%  
Current ratio x4.45.5 79.3%  
Inventory Days Days45131 34.4%  
Debtors Days Days3486 39.5%  
Net fixed assets Rs m15025,797 0.6%   
Share capital Rs m123531 23.2%   
"Free" reserves Rs m7,46968,962 10.8%   
Net worth Rs m7,59269,493 10.9%   
Long term debt Rs m00-   
Total assets Rs m9,82480,383 12.2%  
Interest coverage x54.9531.0 10.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 81.2%   
Return on assets %5.416.9 32.2%  
Return on equity %6.819.5 35.0%  
Return on capital %11.526.7 43.0%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m5841,238 0.1%   
Fx outflow Rs m1,32612,405 10.7%   
Net fx Rs m-1,26928,833 -4.4%   
CASH FLOW
From Operations Rs m-1,9439,543 -20.4%  
From Investments Rs m2,742-6,854 -40.0%  
From Financial Activity Rs m-298-2,459 12.1%  
Net Cashflow Rs m501230 218.3%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.8 16.9%  
FIIs % 1.6 19.0 8.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.2 125.0%  
Shareholders   41,647 31,796 131.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   GLENMARK PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON   FULFORD INDIA  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

This Smallcap Tech Firm has Risen to the Coronavirus Challenge(Profit Hunter)

Apr 7, 2020

This smallcap tech firm is all set to emerge stronger from the Coronavirus crisis.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Apr 9, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - JUBILANT LIFE SCIENCES COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS